U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H28O2
Molecular Weight 288.4251
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TESTOSTERONE

SMILES

C[C@@]12CCC(=O)C=C2CC[C@@]3([H])[C@]4([H])CC[C@@]([H])([C@@]4(C)CC[C@@]31[H])O

InChI

InChIKey=MUMGGOZAMZWBJJ-DYKIIFRCSA-N
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H28O2
Molecular Weight 288.4251
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including

Testosterone is a steroid sex hormone found in both men and women. In men, testosterone is produced primarily by the Leydig (interstitial) cells of the testes when stimulated by luteinizing hormone (LH). It functions to stimulate spermatogenesis, promote physical and functional maturation of spermatozoa, maintain accessory organs of the male reproductive tract, support development of secondary sexual characteristics, stimulate growth and metabolism throughout the body and influence brain development by stimulating sexual behaviors and sexual drive. In women, testosterone is produced by the ovaries (25%), adrenals (25%) and via peripheral conversion from androstenedione (50%). Testerone in women functions to maintain libido and general wellbeing. Testosterone exerts a negative feedback mechanism on pituitary release of LH and follicle-stimulating hormone (FSH). Testosterone may be further converted to dihydrotestosterone or estradiol depending on the tissue. The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects. Testosterone is used as hormone replacement or substitution of diminished or absent endogenous testosterone. Use in males: For management of congenital or acquired hypogonadism, hypogonadism associated with HIV infection, and male climacteric (andopause). Use in females: For palliative treatment of androgen-responsive, advanced, inoperable, metastatis (skeletal) carcinoma of the breast in women who are 1-5 years postmenopausal; testosterone esters may be used in combination with estrogens in the management of moderate to severe vasomotor symptoms associated with menopause in women who do not respond to adequately to estrogen therapy alone.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P10275
Gene ID: 367
Gene Symbol: AR
Target Organism: Homo sapiens (Human)
3.16000000000000014 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TESTOSTERONE

Approved Use

Testosterone is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: • Primary Hypogonadism (Congenital or Acquired) (1) • Hypogonadotropic Hypogonadism (Congenital or Acquired)

Launch Date

1359504000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
13.1 pg/mL
8.2 mg single, topical
dose: 8.2 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
TESTOSTERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
214 ng/dL
30 mg single, topical
dose: 30 mg
route of administration: topical
experiment type: single
co-administered:
TESTOSTERONE unknown
Homo sapiens
population: healthy
age:
sex:
food status:
231 ng/dL
30 mg single, topical
dose: 30 mg
route of administration: topical
experiment type: single
co-administered:
TESTOSTERONE unknown
Homo sapiens
population: healthy
age:
sex:
food status:
930.1 ng/dL
5 g 1 times / day multiple, topical
dose: 5 g
route of administration: topical
experiment type: multiple
co-administered:
TESTOSTERONE unknown
Homo sapiens
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
948 pg × h/mL
8.2 mg single, topical
dose: 8.2 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
TESTOSTERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
2120 ng*h/dL
30 mg single, topical
dose: 30 mg
route of administration: topical
experiment type: single
co-administered:
TESTOSTERONE unknown
Homo sapiens
population: healthy
age:
sex:
food status:
3110 ng*h/dL
30 mg single, topical
dose: 30 mg
route of administration: topical
experiment type: single
co-administered:
TESTOSTERONE unknown
Homo sapiens
population: healthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 h
8.2 mg single, topical
dose: 8.2 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
TESTOSTERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
13%
8.2 mg single, topical
dose: 8.2 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
TESTOSTERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
75 mg 1 times / day steady, subcutaneous
Recommended
dose: 75 mg 1 times / day
route: subcutaneous
experiment_type: steady
dose_type: Recommended
co-adm with
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/30296416/
    unhealthy, adult
    population: unhealthy
    age: adult
    sex: M
    food_status:
    n:
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/30296416/
    Disc. AE: Hypertension...
    AEs leading to
    discontinuation/dose reduction:​
    Hypertension (5.6%)

    data_source:
    https://pubmed.ncbi.nlm.nih.gov/30296416/
    100 mg 1 times / day steady, topical
    Recommended
    dose: 100 mg 1 times / day
    route: topical
    experiment_type: steady
    dose_type: Recommended
    co-adm with
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/20592293/
      unhealthy, mean 74 years
      population: unhealthy
      age: mean 74 years
      sex: M
      food_status:
      n:
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/20592293/
      Other AEs: Cardiac disorders, Atherosclerosis...
      Other AEs:
      Cardiac disorders (6.5%)
      Atherosclerosis (6.4%)

      data_source:
      https://pubmed.ncbi.nlm.nih.gov/20592293/
      AEs

      AEs

      AESignificanceDosePopulation
      Atherosclerosis 6.4%
      100 mg 1 times / day steady, topical
      Recommended
      dose: 100 mg 1 times / day
      route: topical
      experiment_type: steady
      dose_type: Recommended
      co-adm with
        data_source:
        https://pubmed.ncbi.nlm.nih.gov/20592293/
        unhealthy, mean 74 years
        population:
        age:
        sex:
        food_status:
        n:
        data_source:
        https://pubmed.ncbi.nlm.nih.gov/20592293/
        Cardiac disorders 6.5%
        100 mg 1 times / day steady, topical
        Recommended
        dose: 100 mg 1 times / day
        route: topical
        experiment_type: steady
        dose_type: Recommended
        co-adm with
          data_source:
          https://pubmed.ncbi.nlm.nih.gov/20592293/
          unhealthy, mean 74 years
          population:
          age:
          sex:
          food_status:
          n:
          data_source:
          https://pubmed.ncbi.nlm.nih.gov/20592293/
          Hypertension 5.6%
          Disc. AE
          75 mg 1 times / day steady, subcutaneous
          Recommended
          dose: 75 mg 1 times / day
          route: subcutaneous
          experiment_type: steady
          dose_type: Recommended
          co-adm with
            data_source:
            https://pubmed.ncbi.nlm.nih.gov/30296416/
            unhealthy, adult
            population:
            age:
            sex:
            food_status:
            n:
            data_source:
            https://pubmed.ncbi.nlm.nih.gov/30296416/
            Overview

            Overview

            CYP3A4CYP2C9CYP2D6hERG

            Drug as perpetrator​Drug as victim

            Drug as victim

            TargetModalityActivityMetaboliteClinical evidence
            major [Km 10 uM]
            major [Km 38.7 uM]
            minor
            minor
            minor
            minor
            minor
            minor
            minor
            minor
            no
            no
            no
            no
            no
            no
            no
            no
            yes
            yes
            yes
            yes
            PubMed

            PubMed

            TitleDatePubMed
            Effects of estrogenic (o,p'-DDT; octylphenol) and anti-androgenic (p,p'-DDE) chemicals on indicators of endocrine status in juvenile male summer flounder (Paralichthys dentatus).
            2001 Apr
            Psychophysiological responses to the Stroop Task after a maximal cycle ergometry in elite sportsmen and physically active subjects.
            2001 Feb
            Spz1, a novel bHLH-Zip protein, is specifically expressed in testis.
            2001 Feb
            Effects of the anti-androgen finasteride on the modulatory actions of oestradiol on androgen metabolism by human gingival fibroblasts.
            2001 Feb
            Androgens and the role of female "hyperaggressiveness" in spotted hyenas (Crocuta crocuta).
            2001 Feb
            Interactions among paternal behavior, steroid hormones, and parental experience in male marmosets (Callithrix kuhlii).
            2001 Feb
            Castration in Gambel's and Scaled Quail: ornate plumage and dominance persist, but courtship and threat behaviors do not.
            2001 Feb
            cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450.
            2001 Feb
            Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping.
            2001 Feb
            Claudin-1 is not restricted to tight junctions in the rat epididymis.
            2001 Feb
            Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members.
            2001 Feb
            Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes.
            2001 Feb
            Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios.
            2001 Feb
            Photoperiod-induced testicular apoptosis in European starlings (Sturnus vulgaris).
            2001 Feb
            Neuroendocrine regulation of sexually dimorphic brain structure and associated sexual behavior in male rats is genetically controlled.
            2001 Feb
            Influence of the degree of stimulation of the pituitary by gonadotropin-releasing hormone on the action of inhibin and testosterone to suppress the secretion of the gonadotropins in rams.
            2001 Feb
            Follicular-fluid factors and granulosa-cell gene expression associated with follicle deviation in cattle.
            2001 Feb
            Substitution mutation C268Y causes 17 beta-hydroxysteroid dehydrogenase 3 deficiency.
            2001 Feb
            Sex differences in androgen receptors of the human mamillary bodies are related to endocrine status rather than to sexual orientation or transsexuality.
            2001 Feb
            Plasma melatonin concentration before and during testosterone replacement in Klinefelter's syndrome: relation to hepatic indolamine metabolism and sympathoadrenal activity.
            2001 Feb
            Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.
            2001 Feb
            Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause.
            2001 Feb
            Androgen deficiency in women with hypopituitarism.
            2001 Feb
            Muting of androgen negative feedback unveils impoverished gonadotropin-releasing hormone/luteinizing hormone secretory reactivity in healthy older men.
            2001 Feb
            Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance.
            2001 Feb
            Disparate response of wild-type and variant forms of LH to GnRH stimulation in individuals heterozygous for the LHbeta variant allele.
            2001 Feb
            Estrogen and androgen elicit growth hormone release via dissimilar patterns of hypothalamic neuropeptide secretion.
            2001 Feb
            Testosterone concentrations in women aged 25-50 years: associations with lifestyle, body composition, and ovarian status.
            2001 Feb 1
            Neuronal size in the spinal nucleus of the bulbocavernosus: direct modulation by androgen in rats with mosaic androgen insensitivity.
            2001 Feb 1
            Luteinizing hormone-dependent activity and luteinizing hormone-independent differentiation of rat fetal Leydig cells.
            2001 Feb 14
            Porcine gonadal and placental isozymes of aromatase cytochrome P450: sub-cellular distribution and support by NADPH-cytochrome P450 reductase.
            2001 Feb 14
            Changes in androgenic steroid profile due to urine contamination by microorganisms: a prospective study in the context of doping control.
            2001 Feb 15
            Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
            2001 Jan
            Long-term remission of ovarian hyperandrogenism after short-term treatment with a gonadotropin-releasing hormone agonist.
            2001 Jan
            Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS.
            2001 Jan
            Concentrations of steroid hormones in layers and biopsies of chelonian egg yolks.
            2001 Jan
            Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
            2001 Jan
            Androgenic anabolic steroids and arterial structure and function in male bodybuilders.
            2001 Jan
            Induction of nuclear transcription factors, cytochrome P450 monooxygenases, and glutathione S-transferase alpha gene expression in Aroclor 1254-treated rat hepatocyte cultures.
            2001 Jan 15
            Expression of the 17beta-hydroxysteroid dehydrogenase type 5 mRNA in the human brain.
            2001 Jan 22
            Distribution of 17beta-hydroxysteroid dehydrogenases in human osteoblast-like cells.
            2001 Jan 22
            Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5.
            2001 Jan 22
            Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
            2001 Jan 22
            Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
            2001 Jan 22
            Pan1b (17betaHSD11)-enzymatic activity and distribution in the lung.
            2001 Jan 22
            17beta-Hydroxysteroid dehydrogenase type 9 and other short-chain dehydrogenases/reductases that catalyze retinoid, 17beta- and 3alpha-hydroxysteroid metabolism.
            2001 Jan 22
            Type 5 17beta-hydroxysteroid dehydrogenase: its role in the formation of androgens in women.
            2001 Jan 22
            Sex difference in the phosphorylation of cAMP response element binding protein (CREB) in neonatal rat brain.
            2001 Jan 26
            Testosterone modulates the dendritic architecture of arcuate neuroendocrine neurons in adult male rats.
            2001 Jan 26
            Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy.
            2001 Jan 9
            Patents

            Sample Use Guides

            In Vivo Use Guide
            Curator's Comment:: can also be injected https://www.drugs.com/pro/testosterone.html
            Starting dose of testosterone gel is 50 mg of testosterone (4 pump
            Route of Administration: Topical
            10 nM Testosterone significantly reduced secretion of BDNF in in human airway smooth muscle
            Substance Class Chemical
            Created
            by admin
            on Fri Jun 25 21:10:15 UTC 2021
            Edited
            by admin
            on Fri Jun 25 21:10:15 UTC 2021
            Record UNII
            3XMK78S47O
            Record Status Validated (UNII)
            Record Version
            • Download
            Name Type Language
            TESTOSTERONE
            EMA EPAR   EP   HSDB   INCI   INN   JAN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
            INN   INCI  
            Official Name English
            TESTOSTERONE [JAN]
            Common Name English
            TESTOSTERONE [EP MONOGRAPH]
            Common Name English
            TESTOSTERONE [MART.]
            Common Name English
            ANDROST-4-EN-3-ONE, 17-HYDROXY-, (17.BETA.)-
            Systematic Name English
            TESTOSTERONE ENANTATE IMPURITY D [EP]
            Common Name English
            INTRINSA
            Brand Name English
            ANDROGEL
            Brand Name English
            TESTOSTERONE [GREEN BOOK]
            Common Name English
            TESTOSTERONE [WHO-DD]
            Common Name English
            ANDROID-T
            Brand Name English
            TESTOSTERONE [EP]
            Common Name English
            LIVENSA
            Brand Name English
            TESTOSTERONE [ORANGE BOOK]
            Common Name English
            TESTOSTERONE [HSDB]
            Common Name English
            TESTOSTERONE [EMA EPAR]
            Common Name English
            NSC-9700
            Code English
            TESTIM
            Code English
            VOGELXO
            Brand Name English
            TESTOSTERONE PROPIONATE IMPURITY C [EP]
            Common Name English
            TESTOSTERONE [INCI]
            Common Name English
            ANDROLAN
            Brand Name English
            17.BETA.-HYDROXYANDROST-4-EN-3-ONE
            Systematic Name English
            NATESTO
            Brand Name English
            TESTICULOSTERONE
            Common Name English
            MERTESTATE
            Common Name English
            VIROSTERONE
            Common Name English
            TESTOSTERONE [USP]
            Common Name English
            TESTOSTERONE [INN]
            Common Name English
            TESTOSTERONE [VANDF]
            Common Name English
            TESTOSTERONE [MI]
            Common Name English
            HOMOSTERONE
            Common Name English
            ANDRODERM
            Brand Name English
            TESTOSTERONE CIII
            USP-RS  
            Common Name English
            Classification Tree Code System Code
            FDA ORPHAN DRUG 52590
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 49043-3
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            NDF-RT N0000175824
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 2990-0
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 76352-4
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 2986-8
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            WHO-VATC QG03EA02
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 34380-6
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 83116-4
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 59229-5
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 25987-9
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            EMA ASSESSMENT REPORTS LIVENSA (SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL )
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 26827-6
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LIVERTOX 944
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 26826-8
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            CFR 21 CFR 862.1680
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 2987-6
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            NCI_THESAURUS C2298
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            NDF-RT N0000008241
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 2993-4
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 49041-7
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 2994-2
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 13486-6
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            FDA ORPHAN DRUG 104197
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 35225-2
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 49042-5
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 59240-2
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            FDA ORPHAN DRUG 523916
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 59233-7
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            WHO-VATC QG03BA03
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 2988-4
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 16286-7
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 15095-3
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 31030-0
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            WHO-ATC G03EA02
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            WHO-ATC G03BA03
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 73570-4
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 2984-3
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 15432-8
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 2991-8
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 14914-6
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 41018-3
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 35224-5
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 2992-6
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 17685-9
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 59219-6
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            EMA ASSESSMENT REPORTS INTRINSA (WITHDRAWN: SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL)
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 48357-8
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            FDA ORPHAN DRUG 94595
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 10631-0
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 51005-7
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            WHO-ESSENTIAL MEDICINES LIST 18.2
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 27306-0
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            CFR 21 CFR 862.1430
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 70239-9
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            CFR 21 CFR 310.528
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 70240-7
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 15094-6
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 2985-0
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 2989-2
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 6891-6
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 83115-6
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 14913-8
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 17687-5
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            DEA NO. 4000
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            LOINC 25986-1
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            NDF-RT N0000000146
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            Code System Code Type Description
            ECHA (EC/EINECS)
            200-370-5
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            WIKIPEDIA
            TESTOSTERONE
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            CAS
            58-22-0
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            MESH
            D013739
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            HSDB
            3398
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            IUPHAR
            2858
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            DRUG BANK
            DB00624
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            INN
            1900
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            NCI_THESAURUS
            C862
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            FDA UNII
            3XMK78S47O
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            PUBCHEM
            6013
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            ChEMBL
            CHEMBL386630
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            LACTMED
            Testosterone
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            EPA CompTox
            58-22-0
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            RXCUI
            10379
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY RxNorm
            USP_CATALOG
            1646009
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY USP-RS
            EVMPD
            SUB10937MIG
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            DRUG CENTRAL
            2607
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY
            MERCK INDEX
            M10594
            Created by admin on Fri Jun 25 21:10:15 UTC 2021 , Edited by admin on Fri Jun 25 21:10:15 UTC 2021
            PRIMARY Merck Index
            Related Record Type Details
            TRANSPORTER -> INHIBITOR
            METABOLIC ENZYME -> SUBSTRATE
            METABOLIC ENZYME -> SUBSTRATE
            Related Record Type Details
            METABOLITE -> PARENT
            In reproductive tissues, dihydrotestosterone is further metabolized to 3-alpha and 3-beta androstanediol
            METABOLITE TOXIC -> PARENT
            Metabolite shown to induce pyrogenic and inflammatory reactions in man.
            PARENT -> METABOLITE
            URINE
            METABOLITE ACTIVE -> PARENT
            DHT binds with greater affinity to SHBG than does testosterone
            MAJOR
            METABOLITE -> PARENT
            In reproductive tissues, dihydrotestosterone is further metabolized to 3-alpha and 3-beta androstanediol
            METABOLITE -> PARENT
            PRODRUG -> METABOLITE ACTIVE
            METABOLITE ACTIVE -> PARENT
            PRODRUG -> METABOLITE ACTIVE
            METABOLITE -> PARENT
            Related Record Type Details
            IMPURITY -> PARENT
            CHROMATOGRAPHIC PURITY (HPLC/UV)
            EP
            IMPURITY -> PARENT
            CHROMATOGRAPHIC PURITY (HPLC/UV)
            EP
            IMPURITY -> PARENT
            CHROMATOGRAPHIC PURITY (HPLC/UV)
            EP
            IMPURITY -> PARENT
            CHROMATOGRAPHIC PURITY (HPLC/UV)
            EP
            IMPURITY -> PARENT
            CHROMATOGRAPHIC PURITY (HPLC/UV)
            EP
            IMPURITY -> PARENT
            CHROMATOGRAPHIC PURITY (TLC)
            EP
            IMPURITY -> PARENT
            CHROMATOGRAPHIC PURITY (TLC)
            EP
            PARENT -> IMPURITY
            CHROMATOGRAPHIC PURITY (HPLC/UV)
            EP
            IMPURITY -> PARENT
            CHROMATOGRAPHIC PURITY (HPLC/UV)
            EP
            IMPURITY -> PARENT
            CHROMATOGRAPHIC PURITY (HPLC/UV)
            EP
            PARENT -> IMPURITY
            CHROMATOGRAPHIC PURITY (HPLC/UV)
            EP
            IMPURITY -> PARENT
            CHROMATOGRAPHIC PURITY (HPLC/UV)
            EP
            Related Record Type Details
            ACTIVE MOIETY